The role of vaccines in elimination and global eradication of measles: A review of literature

African Journal of Pharmacy and Pharmacology

Volumn 3, Issue 9, 2009, Pages 413-425

  Okonko, I O ^a   Onoja, B A ^a   Adedeji, A O ^a   Ogun, A A ^a   Udeze, A O ^b   Ejembi, J ^c   Garba, K N ^a   Egun, O C ^a   Fowotade, A ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF ILORIN   (Nigeria)

^c AHMADU BELLO UNIVERSITY   (Nigeria)

Author keywords

Antibody; Elimination; Eradication; Immunization; Measles; Measles vaccine; Measles virus; Vaccination

Indexed keywords

HUMAN IMMUNOGLOBULIN; INACTIVATED VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; RETINOL;

BLINDNESS; CLINICAL TRIAL; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INJURY; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; MASS IMMUNIZATION; MEASLES; MORBIDITY; MORTALITY; MUMPS; NONHUMAN; PROPHYLAXIS; REVIEW; RUBELLA; VITAMIN SUPPLEMENTATION;

EID: 77953658405     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. th December, 2008. Ibadan University Press p. 34.
2. Anand S, Bärnighausen T (2007). Health workers and vaccination coverage in developing countries: an econometric analysis. Lancet 369: 1277-1285. (Pubitemid 46553847)
3. Babbott Jr. FL, Gordon JE (1954). "Modern measles". Am. J. Med. Sci. 228 (3): 334-361.
4. Banatvala JE, Brown DW (2004). "Rubella". Lancet. 363 (9415): 1127-1137
5. Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR (1985). "Health impact of measles vaccination in the United States" Pediatrics. 76(4): 524-532. (Pubitemid 15248225)
6. Bolotovskii VM, Gelikman BG, Auzinia AV, Glinskaia EV (1990). The duration and strength of postvaccinal measles immunity. Article in Russian]. Zh. Mikrobiol. Epidemiol. Immunobiol. (5): 32-37.
7. Bonu S, Rani M, Baker TD (2003). The impact of the national polio immunization campaign on levels and equity in immunization coverage: evidence from rural North India. Soc Sci Med. 7: 1807-1819. (Pubitemid 37117334)
8. Brugha R, Starling M, Walt G (2002). GAVI, the first steps: lessons for the Global Fund. Lancet. 359: 435-438. (Pubitemid 34158959)
9. Centers for Disease Control and Prevention (CDC) (1997a). Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, Pan Am. Health Organ. CDC. MMWR 46 (11): 1-21.
10. Centers for Disease Control and Prevention (CDC) (1997b). Progress toward global measles control and elimination. MMWR 46: 893-897. (Pubitemid 127458159)
11. Centers for Disease Control and Prevention (CDC, 1998). Advances in global measles control and elimination: summary of the 1997 international meeting. MMWR 47(11): 1-23.
12. Centers for Disease Control and Prevention (CDC) (2000a). Measles - United States. MMWR 49: 557-560.
13. Centers for Disease Control and Prevention (CDC) (2000b). Progress toward interrupting indigenous measles transmission: Region of the Americas. MMWR. 49: 986-990.
14. Centers for Disease Control and Prevention (CDC) (2001). Progress toward interrupting indigenous measles transmission, region of the Americas. MMWR 50: 1133-1137.
15. Centers for Disease Control and Prevention (CDC) (2004a). "MMR vaccine questions and answers". http://cdc.gov/vaccines/vpdvac/combo- vaccines/mmr/faqs-mmr-hcp.htm. Retrieved on 2009/04/11
16. Centers for Disease Control and Prevention (CDC) (2006a). "Progress in reducing global measles deaths. MMWR Morb Mortal Wkly Rep. 55(9): 247-249.
17. Centre for Global Development (2005). Making Markets for vaccines: from ideas to actions. Centre for Global Development; Washington DC.
18. Centers for Disease Control and Prevention (CDC) (2008a). Progress towards interruption of wild poliovirus transmission worldwide. January 2007-April 2008. MMWR Wkly 57: 489-494.
19. Centers for Disease Control and Prevention (CDC) (2008b). Progress towards poliomyelitis eradication -Nigeria. MMWR Wkly. 57 (34): 942-946.
20. Chalmers I (2002). Why we need to know whether prophylactic antibiotics can reduce measles- related morbidity. Pediatrics 109: 312-315.
21. Commonwealth of Australia (2000). Guidelines for the control of measles outbreaks in Australia. Communicable Diseases Network, Australia New Zealand, Technical Report Series 5: Canberra: Commonwealth Department of Health and Aged Care pp. 1-136.
22. Cutts FT, Markowitz LE (1994). Successes and failures in measles control. J. Infect Dis. 170(1): 32-41
23. Demicheli V, Jefferson T, Rivetti A, Price D (2005). "Vaccines for measles, mumps and rubella in children" . Lay summary - Abstract and plain language summary. Cochrane Database Syst. Rev.19(4): Cochrane Database Systematic Reviews 2005 19(4) Issue 4. Art. No.: CD004407.. doi:10.1002/ 14651858.CD004407.pub2. PMID 16235361. www.cochrane.org/reviews/en/ab004407. html. Retrieved 2009 July 14.
24. Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP (1990). Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 263(18): 2467-71; 264(17): 2211-2212.
25. Ellison RT (2007). The Success of Vaccine Programs in the U.S. J. Watch Infect. Dis. 12: 25.
26. Erdman DD, Xu W, Gerber SI, Gray GC, Schnurr D, Kajon AE (1993). Immunoglobulin M anti-body response to measles virus flowing Primary and secondary vaccination and natural virus infection. J. Med. Virol. 1: 44-48.
27. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988). Small pox and Its eradication. Geneva WHO. Switzerland: World Health Organ. pp. 10-14.
28. Guris D, McCready J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A (1996). Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr. Infect. Dis. J. 15(12): 1082-1086.
29. Hamkar R, Mahmoodi M, Nategh R, Jelyani KN, Eslami MB, Mohktari-Azad T (2006). Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay. WHO Eastern Mediterr. Health J. 12 (6): 775-782.
30. Heinonen OP, Paunio M, Peltola H (1998). Total elimination of measles in Finland. Ann. Med. 30(2): 131-133.
31. Helfand RF, Heath JL, Anderson LJ, Maes EF, Guris D, Bellini WJ (1997). Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J Inf. Dis. 175: 195-199. (Pubitemid 27020848)
32. Hennessey KA, Ion-Nedelcu N, Craciun MD, Toma F, Wattigney W, Strebel PM (1999). Measles epidemic in Romania, assessment of vaccine effectiveness by case-control and cohort studies. Am. J. Epidemiol. 150(11): 1250-1257.
33. Hidaka Y, Aoki T, Akeda H, Miyazaki C, Ueda K (1994) Serological and clinical characteristics of measles vaccine failure in Japan. Scand. J. infect. Dis. 26: 725-730.
34. Katz SL (2005). A Vaccine-Preventable Infectious Disease Kills Half a Million Children Annually. The J. Infect. Dis. 192: 1679-1680.
35. Kerksiek K (2009). Vaccine fatigue: the danger of measles. http://www.infection research.de/perspectives/ detail/pressrelease/ vaccine-fatigue-the-danger-of-measles/March.pdf.
36. Klein NP, Yih WK, Marin M, Jumaan AO, Seward JF, Broder K, Iskander J, Snider Jr. DE, (2008). "Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine". http://www.cdc.gov /mmwr/preview/mmwrhtml/mm5710a3.htm. Morb Mortal Wkly Rep 57 (10): 258-260
37. Liashenko VA, Krasnova VP, Youminova NV (1999). Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16. J. Hum. Antibodies 9(3): 143-148.
38. Loening WE, Coovadia HM (1983). Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination. Lancet. 2: 324-326.
39. Mathias RG, Meekison WG, Arcand TA, Schechter MT (1989). The role of secondary vaccine failures in measles outbreaks. Am. J. Public Health. 79(4): 475-478.
40. Matsumura T, Nakayama T, Okamoto S, Ito H (2005). Measles vaccine coverage and factors related to uncompleted vaccination among 18-month-old and 36-month-old children in Kyoto, Japan. BMC Public Health 5: 59. (Pubitemid 41074279)
41. Meissner HC, Strebel PM, Orenstein WA (2004). Measles Vaccines and the Potential for Worldwide Eradication of Measles. Pediatrics 114 (4): 1065-1069.
42. Merck C (1990, 1999). "MUMPSVAX (Mumps Virus Vaccine Live) Jeryl Lynn Strain" (PDF). http://www.merck.com/ product/ usa/pi-circulars/m/ mumpsvax/mumpsvax-pi.pdf.
43. Merck C (2006). "Attenuvax Product Sheet". http://www.merck. com/ product/usa/pi-circulars/a/ attenuvax/attenuvax-pi.pdf. Retrieved on 2009/04/11
44. Mrozek-Budzyn D, Kiełtyka A (2008). The relationship between MMR vaccination level and the number of new cases of autism in children. Przegl. Epid. 62(3): 597-604.
45. Moss WJ (2009). Measles Pathogenesis and Control. In: Griffin DE and Oldstone MBA (eds.) Measles Control and the Prospect of Eradication. Curr. Top Microbiol. Immunol. Springer Berlin Heidelberg (330): 173-189.
46. Njoku G (2006). Measles immunization campaign targets 29 million Nigerian children. UNICEF Report. Available from web.ng.undp.org/ mdgs/Mid- Point%20Assessment2000-7.pdf
47. Oldstone MBA (1998). Viruses, plagues, and history. Oxford University Press. New York, USA. pp.73-89.
48. Odusanya OO, Alufohai EF, Meurice FP, Ahonkhai VI (2008). Determinants of vaccination coverage in rural Nigeria. BMC. Public Health 8: 381.
49. Offit PA (2008). A Look at Each Vaccine: MMR (Measles, Mumps and Rubella) Vaccine. A publication of the children hospital of Philadelphia (CHOP). http://www.chop.edu/consumer/jsp/ division/ generic.jsp?id=75727.
50. Okonko IO, Babalola ET, Adedeji A.O, Onoja BA, Ogun A.A, Nkang AO, Adu FD (2008). The role of vaccine derived polioviruses in the global eradication of polio-the Nigeria experience as a case study. Biotechnol. Mol. Biol. Rev. 3(6):135-147.
51. Okonko IO, Motayo BO, Ogundiji OT, Babalola ET, Adedeji AO, Ogun AA, Nkang AO (2009). Global Eradication of Measles: A highly contagious and vaccine preventable Disease-What Went Wrong in Africa? J. Cell and Animal Biol. (in press)
52. Olugbode Michael (2007). Nigeria: Measles Outbreak - Borno's Harvest of Death. This Day (Lagos) OPINION 21 June 2007, on the web 22 June by All Africa Global Media (allAfrica.com).
53. Orenstein WAS, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL (2000) Measles eradication: is it in our future? Am. J. Public Health 90: 1521-1525.
54. Pan American Health Organization (2003). Area of Family and Community Health, Immunization Unit. Public. Absence of transmission of the D9 measles virus in the region of the Americas. Morbidity and Mortality Weekly Report 52: 228-229.
55. Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, Souza VA (2004). Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin. Diagn. Lab. Immunol. 11: 119-122.
56. Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, Salmi A, Peltola H (2000). Secondary measles vac-cine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol. infect. 124(2): 263-271. (Pubitemid 30224135)
57. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V (1994). The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N. Engl. J. Med. 331: 1397-1402
58. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE (2001). Prolonged measles virus shedding in HIV infected children, detected by reverse PCR reaction. J. Infect. Dis., 183:532-538.
59. Pontifical Academy for Life (2005). "Moral reflections on vaccines prepared from cells derived from aborted human foetuses". Center for Bioethics, Catholic University of the Sacred Heart. http://www.academiavita.org/ template.jsp?sez=Documenti&pag=testo /vacc/vacc&lang=english..
60. Pütz MM, Bouche FB, de Swart RL, Muller CP (2003). Experimental vaccines against measles in a world of changing epidemiology. Int. J. Parasitol. 33(5-6): 525-545.
61. Rima BK, Earle JAP, Baczko K, ter Mnellen V, Liebert U, Carstens C, Carabana J, Cabellero M, Celma M, Fernandez-Munoz R (1997). Sequence divergence of MV haemagglutinin during natural evolution and adaptation to cell culture. J. Gen. Virol. 78:97-106.
62. Rota PA, Bellini WJ (2003). Update on the Global Distribution of Genotypes of Wild Type Measles Viruses. J. Infect. Dis. 187(1): 270-276.
63. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT (1999). Health consequences of religious and philosophical exemptions from immunization laws. Individual and societal risk of measles. JAMA 282: 47-53.
64. Shann F, D'Souza RM, D'Souza R (2006). Antibiotics for preventing pneumonia in children with measles. Cochrane Database Syst. Rev. (3): CD001477.
65. Stern AM, Markel H (2005). The History of Vaccines and Immunization: Familiar Patterns, New Challenges. Health Aff. 24(3): 611-621.
66. Strebel P, Cochi S, Grabowsky M, Bilous J, Hersh BS, Okwo-Bele JM, Hoekstra E, Wright P, Katz S (2003). The unfinished measles immunization agenda. J. Infect. Dis. 187: 1-7.
67. Tamin A, Rota PA, Wang ZD, Health JL, Anderson LJ, Bellini WJ (1994). Antigenic Analysis of current wild type and vaccine strains of MV. J. Infect. Dis. 170(4): 795-801.
68. Tesoro LJ, Levin MB, Atkin MD, Katz NS, Cotton JM, Patrick-Miller T, Langer MS (1992, 1993). Should all children receive two measles vaccinations? A study of measles susceptibility in a suburban New Jersey private practice. Clin. Pediatr. (Phila) 31(4): 194-9, 32(8): 509-510
69. Times online (2009). MMR Fact Sheet, from the United Kingdom National Health Service. http//www.timesonline.co.uk/tol/life-and-style/health/ article5683671.ece.
70. Torun SD, Bakirci N (2006). Vaccination coverage and reasons for non-vaccination in a district of Istanbul. BMC. Public Health 6: 125.
71. Van Den HS, Smit C, Van Steenbergen JE, De Melker HE (2002). Hospitalizations during a measles epidemic in the Netherlands, 1999 to 2000. Pediatr. Infect. Dis. J. 21: 1146-1150.
72. Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A (2007). "Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine". Pediatr. Infect. Dis. J. 26(7): 632-638. (Pubitemid 47014166)
73. ViroMed Laboratories (2004). "Selected profiles of cell cultures: WI-38". http://www.viromed.com/ services/product/wi38.htm.
74. Vitek CR, Aduddell M, Brinton MJ, Hoffman RE, Redd SC (1999). Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr. Infect. Dis. J. 18: 620-623.
75. Viviani S, Mendy M, Jack AD, Hall AJ, Montesano R, Whittle HC 2004. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia. Trop. Med. Intl. Health 9(10): 1044-1049.
76. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 351: 637-641. (Pubitemid 28098447)
77. Wen-Bo XU, Azaibi Tamin, Rota JS, Zhang LB, Bellini WJ, Rota PA. (1998). Virus Res. 54: 147-156.
78. White DO, Fenner FJ (1994). Measles. In: Medical Virology 4th Edn. Academic press New York pp. 461-465.
79. Wikipedia (2009). Measles Vaccines. From Wikipedia, the free encyclopedia. http://en.wikipedia.org/wiki/measles-vaccines.
80. World Health Assembly (WHA) (1998). Global eradication of poliomyelitis by the year 2000. Geneva, Switzerland: World Health Organization 41: 28.
81. World Health Organization (WHO) (1995). Clinical research on treatment of measles: report of a meeting. WHO, Geneva. 95: 15.
82. World Health Organization (WHO) (2000). Report of a meeting on research related to measles control and elimination, Geneva. The Department of Vaccines and Biologicals, WHO Geneva, WHO/V&B/00.31. www.who.int/vaccines-documents/ who/v&b/00.31
83. World Health Organization (WHO) (2002). Global measles mortality reduction and regional elimination, part I. Wkly Epidemiol. Rec. 77: 50-55.
84. World Health Organization (WHO) (2004). "Global Polio Eradication Initiative." http//:www.polioeradication.org.
85. World Health Organization (WHO)/AFRO-Regional Office for Africa (2004). Guidelines for Measles Surveillance. WHO/AFRO-Regional Office for Africa.
86. World Health Organization (WHO) (2006). Progress in reducing global measles deaths: 1999-2004. Wkly. Epidemiol. Rec. 81(10): 90-94.
87. World Health Organization (WHO) (2007). Measles. WHO Fact sheet No 286.
88. World Health Organization (WHO) (2009). Immunization, vaccines and biologicals. http://www.who.int/immunization/en/vaccinnes.
89. Young ML, Dickstein B, Weibel RE, Stokes J Jr., Buynak EB, Hilleman MR (1967). "Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic". Pediatrics 40 (5): 798-803.